REGENXBIO reports positive topline pivotal data for RGX-202 in Duchenne study

REGENXBIO reports positive topline pivotal data for RGX-202 in Duchenne study
REGENXBIO shares RGX-202 data

REGENXBIO announced positive topline pivotal data from its RGX-202 program for Duchenne muscular dystrophy.

The company highlighted its participation at the FUTURES National Conference, hosted by CureDuchenne, where REGENXBIO team members engaged with families, advocates, and researchers to share and discuss these data. The event brought together the Duchenne community, reflecting ongoing efforts to advance treatments for the condition. Details on the results were shared as part of the company’s commitment to collaboration and transparency.

REGENXBIO previously participated in the ASGCTherapy Annual Meeting, where company representatives engaged with peers in gene therapy research. The event served as a platform for driving discussions on potential advancements. Company activity at industry gatherings remains focused on research and collaboration.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.